Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiation

International Journal of Cancer

Volumn 106, Issue 5, 2003, Pages 723-728

  Gong, Hong ^a,b   Pöttgen, Christoph ^a   Stüben, Georg ^a   Havers, Werner ^a   Stuschke, Martin ^a   Schweigerer, Lothar ^a,c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Angiogenesis; Arginine deiminase; Irradiation; Neuroblastoma; Tumor hypoxia

Indexed keywords

ANGIOGENESIS INHIBITOR; ARGININE DEIMINASE; HOE 33342; MONOCLONAL ANTIBODY DC101; SEMAXANIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CELL PROLIFERATION; DRUG EFFECT; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IRRADIATION; NEUROBLASTOMA; ONCOGENE; PRIORITY JOURNAL; STEM CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; CELL HYPOXIA; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROLASES; INDOLES; MICE; MICE, NUDE; NEUROBLASTOMA; PROTEIN-TYROSINE KINASES; PYRROLES; TUMOR CELLS, CULTURED; WHOLE-BODY IRRADIATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0043025225     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11298     Document Type: Article

References (41)

1. Hayes FA, Smith EI. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and pediatric oncology. Philadelphia: Lippincott, 1989. 607-22.
2. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 1989;41:153-74.
3. Pinkerton CR. Where next with therapy in advanced neuroblastoma? Br J Cancer 1990;61:351-3.
4. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997;19:428-32.
5. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000:59:1261-77.
6. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
7. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
8. Schwab M. Molecular cytogenetics of human neuroblastoma. Biochim Biophys Acta 1992;1114:43-50.
9. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984;81:4940-4.
10. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990;50:4411-6.
11. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994;4:207-18.
12. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996;87:1153-5.
13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
14. Schweigerer L. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 1995;73:497-508.
15. Gospodarowicz D, Neufeld G, Schweigerer L. Fibroblast growth factor. Mol Cell Endocrinol 1986;46:187-204.
16. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997;18:4-25.
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
18. Hasumi Y, Mizukami H, Urabe M, Kohno T, Takeuchi K, Kume A, Momoeda M, Yoshikawa H, Tsuruo T, Shibuya M, Taketani Y, Ozawa K. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002;62:2019-23.
19. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-800.
20. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D'Amato R, Folkman J, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001;98:4605-10.
21. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
22. Fotsis T, Breit S, Lutz W, Rossler J, Hatzi E, Schwab M, Schweigerer L. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur J Biochem 1999;263:757-64.
23. Rossler J, Breit S, Havers W, Schweigerer L. Vascular endothelial growth factor expression in human neuroblastoma: up-regulation by hypoxia. Int J Cancer 1999;81:113-7.
24. Breit S, Ashman K, Wilting J, Rossler J, Hatzi E, Fotsis T, Schweigerer L. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 2000;60:4596-601.
25. Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takihara K, Ziche M, Rofstad EK, et al. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene 2002;21:3552-61.
26. Hatzi E, Breit S, Zoephel A, Ashman K, Tontsch U, Ahorn H, Murphy C, Schweigerer L, Fotsis T. MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells: purification, structural, and functional characterization. Adv Exp Med Biol 2000;476:239-48.
27. Hatzi E, Murphy C, Zoephel A, Ahorn H, Tontsch U, Bamberger AM, Yamauchi-Takihara K, Schweigerer L, Fotsis T. N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma. Eur J Biochem 2002;269:3732-41.
28. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
29. Gong H, Zolzer F, von Recklinghausen G, Rossler J, Breit S, Havers W, Fotsis T, Schweigerer L. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 1999;261:10-4.
30. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth, KP et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
31. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.
32. Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M. Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature 1996;379:466-9.
33. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993;90:2690-4.
34. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer, L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997;57:2916-21.
35. Stuben G, Thews O, Pottgen C, Knuhmann K, Vaupel P, Stuschke M. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-50.
36. Bernsen HJ, Rijken PF, Oostendorp T, van der Kogel AJ. Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br J Cancer 1995;71:721-6.
37. Stuben G, Thews O, Pottgen C, Stuschke M, Sack H. Tumour oxygenation during fractionated radiotherapy: comparison with size-matched controls. Acta Oncol 1999;38:209-13.
38. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
39. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-68.
40. Rockwell S. Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol Res 1997;9:383-90.
41. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997;37:1107-13.